Chloramphenicol and Oxazolidinones

Chloramphenicol binds reversibly to the 50S ribosomal subunit, blocking peptide chain elongation.

The binding site overlaps substantially with those of macrolides and lincosamides, which has two practical consequences. The overlap in binding region explains why these drug classes can antagonize each other in combination and why ribosomal modification resistance can confer cross-resistance to all three classes.

The effect is reversible and bacteriostatic against most organisms. However, chloramphenicol is bactericidal against Haemophilus influenzae, Neisseria meningitidis, and Streptococcus pneumoniae at clinical concentrations — an exception to its generally bacteriostatic character that is clinically relevant for meningitis treatment.

Chloramphenicol has a genuinely broad spectrum spanning aerobic Gram-positive and Gram-negative bacteria, anaerobes, and intracellular organisms including rickettsiae. This breadth distinguishes it from most other protein synthesis inhibitors.

Among Gram-negative organisms, it is active against H. influenzae, N. meningitidis, S. pneumoniae, many Enterobacteriaceae, and Salmonella typhi — though resistance to S. typhi has emerged substantially in endemic regions. Activity against anaerobes including Bacteroides fragilis makes it useful for polymicrobial infections in resource-limited settings. Chloramphenicol retains activity against rickettsial organisms, though doxycycline has supplanted it as the preferred agent for Rocky Mountain spotted fever due to superior outcomes. It does not have reliable activity against Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus.

Chloramphenicol is well absorbed orally. For intravenous use it is administered as the chloramphenicol succinate prodrug, which requires hydrolysis by esterases to release the active form; this conversion is variable and can yield lower plasma levels than oral dosing. Chloramphenicol achieves cerebrospinal fluid concentrations of approximately 30 to 50% of simultaneous plasma concentrations even without meningeal inflammation, rising toward plasma levels when the meninges are inflamed. This degree of penetration is clinically distinctive. It also distributes freely into brain parenchyma, bile, and placental circulation.

Chloramphenicol is metabolized primarily in the liver by glucuronosyltransferase enzymes, which conjugate it to an inactive glucuronide that is then renally excreted. Hepatic impairment prolongs the half-life and increases toxicity risk; dose reduction is required in significant liver disease. Serum level monitoring is recommended when chloramphenicol is used in neonates or patients with hepatic dysfunction.

In neonates, particularly premature infants, the hepatic glucuronidation pathway is immature and substantially underdeveloped. When neonates receive doses appropriate for older patients, chloramphenicol accumulates to toxic levels, producing gray baby syndrome — a potentially fatal toxicity characterized by abdominal distension, vomiting, refusal to feed, cyanosis, cardiovascular collapse, and a characteristic ashen-gray skin discoloration.

The underlying mechanism is inhibition of mitochondrial protein synthesis in cardiac and skeletal muscle, producing a direct myocardial depressant effect. This is the same mechanism by which chloramphenicol causes dose-dependent bone marrow suppression — the drug inhibits the mitochondrial ribosomes, which are structurally similar to bacterial 70S ribosomes. Gray baby syndrome can also occur in older patients receiving excessively high doses, though immature metabolism is the primary risk factor.

Chloramphenicol produces dose-dependent, reversible suppression of all three hematopoietic cell lines through inhibition of mitochondrial protein synthesis in bone marrow precursor cells. This toxicity is predictable, occurs in a concentration-dependent fashion, and is fully reversible upon stopping the drug. It is detectable by serum level monitoring — plasma concentrations above approximately 25 micrograms per milliliter are associated with this effect.

Chloramphenicol-associated aplastic anemia is an idiosyncratic reaction entirely unrelated to dose or plasma concentration. It occurs at a rate of approximately 1 in 25,000 to 1 in 40,000 treatment courses. The reaction typically presents weeks to months after drug exposure — often after the course is completed — making causality difficult to establish in retrospect.

The mechanism involves toxic effects of chloramphenicol metabolites on hematopoietic stem cells, producing irreversible destruction of the bone marrow. Mortality exceeds 50% without bone marrow transplantation or immunosuppressive therapy. Serum level monitoring has no impact on this reaction — it cannot be prevented or predicted by laboratory surveillance. This is the primary reason systemic chloramphenicol use has been curtailed in high-income countries.

Chloramphenicol is a potent inhibitor of cytochrome P450 enzymes including CYP2C19, which metabolizes phenytoin, warfarin, and other narrow-therapeutic-index drugs. Co-administration with phenytoin produces phenytoin toxicity — nystagmus, ataxia, and altered consciousness — through reduced phenytoin clearance. Warfarin anticoagulation is substantially enhanced. These interactions require close monitoring or avoidance of combination therapy.

In high-income countries, systemic chloramphenicol is reserved for situations where no safer alternative exists: bacterial meningitis in patients with severe beta-lactam allergy who cannot receive cephalosporins; typhoid fever in regions with multidrug-resistant Salmonella typhi where alternatives are unavailable; and brain abscess, where its central nervous system penetration and anaerobic coverage are difficult to replicate. Topical chloramphenicol (eye drops and ointment) remains widely used for bacterial conjunctivitis without the systemic toxicity concerns. In low-income countries, oral and injectable chloramphenicol continue as essential medicines for meningitis, typhoid, and serious anaerobic infections where cost limits alternatives.

Oxazolidinones bind the 50S ribosomal subunit and block assembly of the 70S initiation complex, preventing translation from beginning. This pre-initiation mechanism is distinct from all prior clinical ribosomal inhibitors, which act during the elongation phase after the complex is assembled.

Because the oxazolidinone binding site on the 50S subunit is distinct from those of macrolides, lincosamides, and chloramphenicol, ribosomal modification resistance to those classes does not confer cross-resistance to oxazolidinones.

The effect is bacteriostatic against staphylococci and enterococci. Against streptococci, linezolid can be bactericidal — an exception with clinical relevance for certain infections.

Oxazolidinones are active exclusively against Gram-positive bacteria. They have no clinically useful activity against Gram-negative organisms because they cannot efficiently penetrate the Gram-negative outer membrane. The spectrum includes MRSA, vancomycin-resistant Staphylococcus aureus, VRE (both Enterococcus faecalis and Enterococcus faecium), penicillin-resistant Streptococcus pneumoniae, Streptococcus pyogenes, and other streptococci.

Linezolid is also active against Mycobacterium tuberculosis and is used in regimens for extensively drug-resistant tuberculosis, exploiting its activity against mycobacterial 23S ribosomal ribonucleic acid. It has no meaningful activity against Gram-negative enteric bacteria, Pseudomonas aeruginosa, or anaerobic Gram-negative bacilli.

Linezolid has approximately 100% oral bioavailability, making it one of the few antibiotics where oral and intravenous formulations are completely interchangeable without dose adjustment. A patient begun on intravenous linezolid can be switched to oral therapy the moment they can tolerate oral intake, with no change in drug exposure. This property reduces cost, eliminates the need for intravenous access, and enables earlier hospital discharge — a clinically significant advantage over vancomycin, which requires intravenous administration throughout treatment.

Linezolid distributes well into skin, soft tissue, lung, and bone. It achieves good cerebrospinal fluid penetration. Linezolid does not undergo cytochrome P450 metabolism and therefore has no cytochrome P450-mediated drug interactions. No dose adjustment is required for renal impairment. Dose adjustment is not required for mild to moderate hepatic impairment.

Tedizolid phosphate is a prodrug converted to the active form tedizolid after oral or intravenous administration. Its half-life is approximately 12 hours, supporting once-daily dosing — an advantage over linezolid's twice-daily regimen. Tedizolid concentrates in macrophages at levels exceeding plasma concentrations, enhancing activity against intracellular staphylococci. Tedizolid is more potent than linezolid, permitting a lower daily dose that reduces the cumulative mitochondrial exposure underlying many of linezolid's adverse effects. No dose adjustment is required for renal or moderate hepatic impairment.

Linezolid causes reversible, dose- and duration-dependent suppression of all hematopoietic cell lines through inhibition of mitochondrial protein synthesis in bone marrow precursors — the same mechanism as chloramphenicol's reversible bone marrow suppression. Thrombocytopenia (low platelet count) is the most consistently observed effect and typically appears after 10 to 14 days of therapy. Anemia and low white blood cell counts can occur with prolonged courses. The suppression is fully reversible on stopping the drug. Weekly complete blood count monitoring is recommended for courses exceeding two weeks. Tedizolid produces significantly less myelosuppression than linezolid, attributed to its lower daily dose reducing cumulative mitochondrial exposure.

Linezolid is a reversible, nonselective monoamine oxidase inhibitor. Monoamine oxidase metabolizes serotonin, dopamine, and norepinephrine in neurons and the gut. When linezolid is combined with serotonergic medications — selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, meperidine, or tramadol — serotonin accumulates and can trigger serotonin syndrome. The classic triad includes mental status changes (agitation, confusion), autonomic instability (hyperthermia, diaphoresis, tachycardia, hypertension), and neuromuscular abnormalities (clonus, hyperreflexia, tremor, myoclonus). Serotonin syndrome can be life-threatening. Linezolid is contraindicated with concurrent use of selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors unless adequate washout has occurred and the clinical need is compelling. Tedizolid also inhibits monoamine oxidase but appears to carry lower clinical risk of serotonin syndrome based on available data.

Prolonged linezolid therapy — generally courses exceeding four weeks, and particularly the months-long courses used for drug-resistant tuberculosis or chronic osteomyelitis — is associated with peripheral neuropathy and optic neuropathy. Both result from mitochondrial dysfunction in neurons. Peripheral neuropathy presents as distal paresthesias and sensory loss in a stocking-glove distribution; if not caught early, it can be irreversible. Optic neuropathy presents with progressive visual loss, color vision disturbance, and central scotoma, and can result in permanent vision impairment. Monthly ophthalmologic and neurological assessment is recommended for courses exceeding four weeks.

Linezolid is approved and widely used for MRSA pneumonia (including ventilator-associated pneumonia), complicated skin and soft tissue infections caused by MRSA, VRE infections, and as an oral option for osteomyelitis caused by MRSA. Clinical data support favorable outcomes with linezolid for MRSA pneumonia compared to vancomycin, attributed partly to better lung penetration and more predictable pharmacokinetics.

Linezolid is not recommended for MRSA bacteremia. Clinical data show inferior outcomes compared to vancomycin or daptomycin for bloodstream infections — a consequence of its bacteriostatic activity against staphylococci. The clinical contexts of MRSA pneumonia and MRSA bacteremia should not be conflated; the superior pneumonia data do not justify use in bacteremia.

Resistance to oxazolidinones among staphylococci and enterococci remains relatively uncommon but is increasing, particularly in Enterococcus faecium. The dominant mechanism is point mutations in the 23S ribosomal ribonucleic acid gene that reduce drug binding affinity. Because bacteria carry multiple copies of the 23S ribosomal ribonucleic acid gene, high-level resistance requires mutations in multiple gene copies simultaneously. Organisms with more copies can accumulate mutations progressively.

A transferable resistance gene originally identified in livestock staphylococci encodes a methyltransferase that modifies the ribosomal binding site, reducing binding of both chloramphenicol and oxazolidinones. This gene represents a clinically important cross-class resistance mechanism. Tedizolid retains activity against some linezolid-resistant organisms carrying single 23S ribosomal ribonucleic acid mutations but not against isolates carrying this transferable resistance gene.